temozolomide has been researched along with Leukemia, Myeloid, Acute in 17 studies
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 43-year-old man with an anaplastic astrocytoma received radiation therapy synchronized with ranimustine and adjuvant TMZ chemotherapy for 15 cycles." | 5.46 | A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma. ( Kosugi, K; Saito, K; Takahashi, W; Tokuda, Y; Tomita, H, 2017) |
| "Twenty patients (16 with acute myelogenous leukemia, two with acute lymphoblastic leukemia, and two with chronic myelogenous leukemia in blastic phase) received 43 cycles of temozolomide." | 5.10 | Phase I study of temozolomide in relapsed/refractory acute leukemia. ( Ahmed, T; Baskind, P; Liu, D; Loughran, T; Seiter, K; Siddiqui, A, 2002) |
| " A pilot clinical study indicates that dacarbazine can induce a marked decrease of leukemic blasts in patients affected by acute myelogenous leukemia (AML) with low pretreatment levels of OGAT activity." | 5.08 | Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. ( Bonmassar, E; Caravita, T; D'Atri, S; Franchi, A; Graziani, G; Papa, G; Piccioni, D, 1995) |
| " Further clinical investigations aimed at elucidating the veliparib exposure-efficacy/safety relationship and optimizing dosing recommendations for maximizing benefit-risk in patients with advanced myeloid malignancies should study veliparib doses ranging up to 120 mg in combination with temozolomide." | 2.90 | Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. ( Beumer, JH; Chen, A; Gobburu, J; Gojo, I; Gopalakrishnan, M; Greer, JM; Karp, JE; Kiesel, BF; Mehrotra, S; Piekarz, R; Rudek, MA; Singh, R, 2019) |
| " Temozolomide, dosed according to MGMT methylation status, demonstrated modest clinical activity in elderly patients with AML, especially in those presenting with fewer comorbidities and low disease burden." | 2.77 | Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. ( Arber, DA; Coutre, SE; Gotlib, J; Kohrt, HE; Medeiros, BC; Zehnder, JL; Zhang, B, 2012) |
| "Treatment with Temozolomide and Lomeguatrib, a potent MGMT inhibitor, produced a huge, although transient, blastolysis and complete disappearance of all skin lesions." | 2.49 | Triazene compounds in the treatment of acute myeloid leukemia: a short review and a case report. ( Aquino, A; Bernardini, S; Bianchi, A; Bonmassar, E; Bonmassar, L; D'Atri, S; Franzese, O; Lattuada, D; Marchesi, F; Margison, GP; Pascale, E, 2013) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "A 43-year-old man with an anaplastic astrocytoma received radiation therapy synchronized with ranimustine and adjuvant TMZ chemotherapy for 15 cycles." | 1.46 | A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma. ( Kosugi, K; Saito, K; Takahashi, W; Tokuda, Y; Tomita, H, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, R | 1 |
| Mehrotra, S | 1 |
| Gopalakrishnan, M | 1 |
| Gojo, I | 1 |
| Karp, JE | 1 |
| Greer, JM | 1 |
| Chen, A | 1 |
| Piekarz, R | 1 |
| Kiesel, BF | 1 |
| Gobburu, J | 1 |
| Rudek, MA | 1 |
| Beumer, JH | 1 |
| Joseph, R | 1 |
| McRee, AJ | 1 |
| Mathews, S | 1 |
| Zeidner, JF | 1 |
| Bonmassar, L | 1 |
| Marchesi, F | 1 |
| Pascale, E | 1 |
| Franzese, O | 1 |
| Margison, GP | 1 |
| Bianchi, A | 1 |
| D'Atri, S | 3 |
| Bernardini, S | 1 |
| Lattuada, D | 1 |
| Bonmassar, E | 2 |
| Aquino, A | 1 |
| Tan, CW | 1 |
| See, SJ | 1 |
| Tham, CK | 1 |
| Ang, AL | 1 |
| Brandwein, JM | 1 |
| Kassis, J | 1 |
| Leber, B | 1 |
| Hogge, D | 1 |
| Howson-Jan, K | 1 |
| Minden, MD | 1 |
| Galarneau, A | 1 |
| Pouliot, JF | 1 |
| Sait, S | 1 |
| Kobos, R | 1 |
| LaQuaglia, MP | 1 |
| Pandit-Taskar, N | 1 |
| Modak, S | 1 |
| Kosugi, K | 1 |
| Saito, K | 1 |
| Takahashi, W | 1 |
| Tokuda, Y | 1 |
| Tomita, H | 1 |
| Seiter, K | 2 |
| Katragadda, S | 1 |
| Ponce, D | 1 |
| Rasul, M | 1 |
| Ahmed, N | 1 |
| Nishikawa, R | 1 |
| Kim, SJ | 1 |
| Park, TS | 1 |
| Lee, ST | 1 |
| Song, J | 1 |
| Suh, B | 1 |
| Kim, SH | 1 |
| Jang, SJ | 1 |
| Lee, CH | 1 |
| Choi, JR | 1 |
| Medeiros, BC | 1 |
| Kohrt, HE | 1 |
| Gotlib, J | 1 |
| Coutre, SE | 1 |
| Zhang, B | 1 |
| Arber, DA | 1 |
| Zehnder, JL | 1 |
| Liu, D | 1 |
| Loughran, T | 1 |
| Siddiqui, A | 1 |
| Baskind, P | 1 |
| Ahmed, T | 1 |
| Noronha, V | 1 |
| Berliner, N | 1 |
| Ballen, KK | 1 |
| Lacy, J | 1 |
| Kracher, J | 1 |
| Baehring, J | 1 |
| Henson, JW | 1 |
| Piccioni, D | 2 |
| Papa, G | 2 |
| Caravita, T | 1 |
| Franchi, A | 2 |
| Graziani, G | 1 |
| Castellano, A | 1 |
| Tuorto, V | 1 |
| Lu, K | 1 |
| Christiansen, N | 1 |
| Frankel, S | 1 |
| Rustum, YM | 1 |
| Tisdale, MJ | 2 |
| Hooper, NI | 1 |
| Thornalley, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Two Distinct Tailored Temozolomide Regimens for Patients With Acute Myeloid Leukemia Age > 60 Years and Poor Risk/Refractory Disease[NCT00611247] | Phase 2 | 42 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Response determined per European LeukemiaNet response criteria:~CR = bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count > 1.0 x 10e9/L; platelet count > 100 x 10e9/L; and independence of red cell transfusions.~CRi = all CR criteria except for residual neutropenia (< 1.0 x 10e9/L) or thrombocytopenia (< 100 x 10e9/L)].~Morphologic leukemia-free state (LFS) = bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; with no hematologic recovery required.~Relapse = bone marrow blasts >5%; reappearance of blasts in the blood; or development of extramedullary disease." (NCT00611247)
Timeframe: up to 2 months
| Intervention | participants (Number) |
|---|---|
| Methylated AGAT Promoter (Group 1) | 3 |
| Un-Methylated AGAT Promoter (Group 2) | 10 |
(NCT00611247)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Methylated AGAT Promoter (Group 1) | 4 |
| Un-Methylated AGAT Promoter (Group 2) | 13 |
(NCT00611247)
Timeframe: 12 months
| Intervention | events (Number) |
|---|---|
| Methylated AGAT Promoter (Group 1) | 4 |
| Un-Methylated AGAT Promoter (Group 2) | 27 |
3 reviews available for temozolomide and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Triazene compounds in the treatment of acute myeloid leukemia: a short review and a case report.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Leukemia, Myeloid, Acute; Male; Mid | 2013 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.
Topics: Aged; Breast Neoplasms; Dacarbazine; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndr | 2006 |
6 trials available for temozolomide and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2019 |
Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survi | 2014 |
Temozolomide and cisplatin in relapsed/refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Resistance | 2009 |
Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bone Marrow; Dacarbazine; DNA Methylatio | 2012 |
Phase I study of temozolomide in relapsed/refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug | 2002 |
Cisplatin increases sensitivity of human leukemic blasts to triazene compounds.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cisplatin; Dacarbazine; D | 1995 |
8 other studies available for temozolomide and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chromosome I | 2019 |
Treatment-related Acute Myeloid Leukaemia After Temozolomide for Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Leuke | 2014 |
Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cytarabine; Dacarbazi | 2017 |
A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Daca | 2017 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; G | 2009 |
Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Dacarbazine; Drug Scr | 1995 |
Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Chlorambucil; Colonic Neoplasms; Dacarbaz | 1987 |
Glyoxalase activity during differentiation of human leukaemia cells in vitro.
Topics: Cell Differentiation; Dacarbazine; Formamides; Humans; Imidazoles; In Vitro Techniques; Lactoylgluta | 1987 |